IPO registrations (S-1, F-1) · Registrants
NEXGEL, INC.
- SEC CIK
- 1468929 · filings on EDGAR ↗
- Former names
- AquaMed Technologies, Inc. (2009–2019)
- Registration
- Form S-1, first filed 2019-01-09, last 2026-08-20; 4 initial registrations, 6 amendments
- Outcome
- Final prospectus filed 2021-12-27; declared effective 2021-05-07; withdrawal requested 2019-06-14
- Industry (SIC)
- Surgical & Medical Instruments & Apparatus 3841
- Incorporated in
- DE
- Business address
- 2150 CABOT BLVD WEST,, SUITE B, Langhorne, PA 19047
- EIN
- 26-4042544
- Ticker
- NXGL, NXGLW (Nasdaq, Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- NEXGEL, INC. on the corporate pages
Offering terms
- Final price
- $5.50 per share (424B4 filed 2021-12-27, an initial public offering)
- Shares sold
- 2,585,000
- Gross proceeds
- $14,217,500 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol NXGL
- Lead underwriters
- Number of Units Maxim Group LLC (2,585,000 shares)
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Business registration: NEXGEL, INC. EXACT (EIN (EXACT, as the state registration reports it))
- Business registration: Nexgel Inc. Fuzzy (name and state)
- Form 5500 plan sponsor: NEXGEL INC EXACT (EIN (EXACT))
- Form D issuer: NEXGEL, INC. EXACT (CIK (EXACT))
- SEC filer: AquaMed Technologies, Inc. EXACT (CIK (EXACT))
Filings 16
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2019-01-09 | S-1 | S-1 (registration) | AquaMed Technologies, Inc. | 0001144204-19-001167 ↗ |
| 2019-03-12 | S-1/A | S-1/A (amendment) | AquaMed Technologies, Inc. | 0001144204-19-013366 ↗ |
| 2019-03-26 | S-1/A | S-1/A (amendment) | AquaMed Technologies, Inc. | 0001144204-19-015831 ↗ |
| 2019-04-19 | S-1/A | S-1/A (amendment) | AquaMed Technologies, Inc. | 0001144204-19-020424 ↗ |
| 2019-06-14 | RW | RW (withdrawal request) | AquaMed Technologies, Inc. | 0001144204-19-031041 ↗ |
| 2021-04-09 | S-1 | S-1 (registration) | NEXGEL, INC. | 0001104659-21-048833 ↗ |
| 2021-05-07 | EFFECT | EFFECT (declared effective) | NEXGEL, INC. | 9999999995-21-001851 ↗ |
| 2021-11-09 | S-1 | S-1 (registration) | NEXGEL, INC. | 0001104659-21-136084 ↗ |
| 2021-12-02 | S-1/A | S-1/A (amendment) | NEXGEL, INC. | 0001104659-21-145979 ↗ |
| 2021-12-06 | S-1/A | S-1/A (amendment) | NEXGEL, INC. | 0001104659-21-146733 ↗ |
| 2021-12-10 | S-1/A | S-1/A (amendment) | NEXGEL, INC. | 0001104659-21-148686 ↗ |
| 2021-12-21 | S-1MEF | S-1MEF (added securities) | NEXGEL, INC. | 0001104659-21-152316 ↗ |
| 2021-12-21 | EFFECT | EFFECT (declared effective) | NEXGEL, INC. | 9999999995-21-004776 ↗ |
| 2021-12-27 | 424B4 | 424B4 (final prospectus) | NEXGEL, INC. | 0001104659-21-153274 ↗ |
| 2023-06-07 | EFFECT | EFFECT (declared effective) | NEXGEL, INC. | 9999999995-23-001655 ↗ |
| 2026-08-20 | S-1 | S-1 (registration) | NEXGEL, INC. | 0001493152-26-039421 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2021-12-10 | S-1/A | registration statement | $1.00 | 2,065,935 | $2,065,935 | Nasdaq NXGL | 0 | primary document; price sentence, shares headline, proceeds computed | document ↗ | |
| 2021-12-27 | 424B4 | final prospectus | $5.50 | 2,585,000 | $14,217,500 | Nasdaq NXGL | 1 | primary document; price sentence, shares headline, proceeds table, underwriting table 1 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Adynxx, Inc. | TenPercentOwner | 1 | 2019 | ||
| Johnson David Ian | Director,Officer | Chief Executive Officer | 1 | 2019 | |
| Stein John Nachum | Director; Director,TenPercentOwner | 13 | 2019–2025 | ||
| BEZALEL PARTNERS LLC | TenPercentOwner | 1 | 2019 | ||
| STEFANSKY DAVID | Director; Director,TenPercentOwner | 12 | 2019–2023 | ||
| Levy Adam R. | Director,Officer; Officer; Officer,TenPercentOwner | CEO; CEO and President; CEO & CFO; Chief Executive Officer | 25 | 2019–2026 | |
| ZELDIS JEROME B | Director | 9 | 2021–2025 | ||
| glassman steven mark | Director | 12 | 2021–2025 | ||
| Drapczuk Adam E III | Officer | Chief Financial Officer | 5 | 2021–2024 | |
| Toledano Miranda Jayne | Director | 3 | 2021–2023 | ||
| Spinrad Yaakov | Director | 2 | 2021–2022 | ||
| Henry Scott Robert | Director | 22 | 2023–2026 | ||
| MCGUIRE JOSEPH F | Officer | Chief Financial Officer | 1 | 2025 | |
| Ciardiello Steven | Director | 1 | 2025 | ||
| Blackman Ian Howard | Officer | Chief Financial Officer | 1 | 2026 | |
| Harris Kevin McClain | Director | 1 | 2026 | ||
| Kieser Brian Joseph | Director | 2 | 2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2021-09-17 | NEXGEL, INC. | Other Health Care | $2,500,000 | $1,620,000 | 20 | 1 |
| 2021-03-23 | NEXGEL, INC. | Biotechnology | $1,500,000 | $1,500,000 | 1 | 1 |
| 2021-03-23 | NEXGEL, INC. | Biotechnology | $515,000 | $515,000 | 12 | 1 |
| 2020-08-21 | NEXGEL, INC. | Biotechnology | $500,000 | $395,100 | 5 | 1 |
| 2019-09-25 | AquaMed Technologies, Inc. | Biotechnology | $750,000 | $175,000 | 2 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Business registration | NEXGEL, INC. | FL | State business registries | EIN (EXACT, as the state registration reports it) |
| Plan sponsor | NEXGEL INC | PA | Form 5500 (employee benefit plans) | EIN (EXACT) |
| Form D issuer | NEXGEL, INC. | PA | Form D private offerings | CIK (EXACT) |
| SEC filer | NEXGEL, INC. | SEC filers (EDGAR) | CIK (EXACT) | |
| Business registration | Nexgel Inc. | State business registries | name and state | |
| Form 5500 plan sponsor | NEXGEL INC | EIN (EXACT) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Surgical & Medical Instruments & Apparatus, PA first:
- VASCULAR SOLUTIONS LLC PA
- BIONX IMPLANTS INC PA
- STRATA Skin Sciences, Inc. PA
- CardioNet, Inc. PA
- Neuronetics, Inc. PA
- GLOBUS MEDICAL INC PA
- Texcel, Inc. PA
- ACCELLENT INC PA
- Power Medical Interventions, Inc. PA
- Unilife Corp PA
In other datasets, the same topic (Technology) in PA:
- Form D issuer: 360fly, Inc. (Form D private offerings)
- Lobbying client: ACA CONNECTS - AMERICA'S COMMUNICATION ASSOCIATION (Federal lobbying (LDA))
Interests: Surgical & Medical Instruments & Apparatus · Technology